MedTrace Logo

Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis

NCT07171112 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-11-10

No results posted yet for this study

Summary

The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.

Conditions

  • Pancreatitis, Chronic
  • Pancreatitis, Acute
  • Recurrent Acute Pancreatitis
  • Smoking (Tobacco) Addiction

Interventions

DRUG

Increased Varenicline Dosing (1mg TID)

Varenicline 1mg PO (oral) three times daily

DRUG

Standard Varenicline Dosing (1 mg BID)

Varenicline PO (oral) 1mg twice daily

DRUG

Bupropion 150 mg twice daily

Bupropion 150 mg PO twice daily

Sponsors & Collaborators

Principal Investigators

  • Samuel Han, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-06
Primary Completion
2027-10-01
Completion
2028-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07171112 on ClinicalTrials.gov